What trial did Avacta Group present at the 25–28 September AACR Conference on Pancreatic Cancer in San Diego?

At the 25–28 September AACR Conference on Pancreatic Cancer in San Diego, Avacta Group presented the design of its FOCUS-01 Phase 1 trial and new preclinical data for AVA6103.

Avacta — TickStock

Timeline

Avacta

12 stories · updated 6d ago

Avacta raises £12.5m in placing and subscription

07:27, 6 Oct 2026

Avacta unveils new AVA6103 data at pancreatic cancer conference

07:29, 25 Sept 2026

Avacta hits clinical proof of mechanism for AVA6103

08:19, 16 Sept 2026

Avacta settles £3.67m convertible bond payment in cash

07:53, 9 Jul 2026

FDA clears single pivotal trial path for Avacta's AVA6000 in salivary gland cancer

07:28, 25 Jun 2026

Avacta starts dosing patients in AVA6103 trial with cash runway extended to early 2027

07:37, 22 Jun 2026

Avacta Group raises £9m to repay debt

07:59, 5 Jun 2026

Avacta reports positive results in salivary gland cancer research

14:22, 1 Jun 2026

Avacta names Richard Hughes as non‑executive chairman

09:17, 29 May 2026

Avacta says pre|CISION releases payload faster and more selectively than approved ADCs

11:09, 6 May 2026

Avacta demonstrates AVA6103 outdelivers Enhertu and reveals dual‑payload in vivo data

07:33, 21 Apr 2026

Avacta to raise c.£10m via equity placing

00:39, 27 Mar 2026

IP Group leads £4m funding round for AI materials spin-out

08:29, 12 Oct 2026

Biotech

Genflow wins Japanese patent allowance for SIRT6 therapy

12:41, 9 Oct 2026

Biotech

Sareum signals intention to launch equity capital raise

09:32, 8 Oct 2026

Biotech

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

13:29, 6 Oct 2026

Biotech

Poolbeg Pharma secures South Korean patent for POLB 001

07:41, 6 Oct 2026

Biotech

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

17:03, 5 Oct 2026

Biotech

Fusion Antibodies relaunches website to sharpen customer focus

08:26, 5 Oct 2026

Regulation & Governance

Cardiogeni shares suspended on delayed annual accounts

09:57, 1 Oct 2026

Biotech

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

08:54, 1 Oct 2026

Biotech

Eden Research wins US label expansion for Mevalone

12:07, 29 Sept 2026

Avacta Group is a clinical-stage life sciences company developing pre|CISION®, a payload delivery system targeting tumors through fibroblast activation protein to concentrate potent cancer therapies while minimizing exposure to normal tissues.

Sector: Biotech
Market: AIM

Insight

What did Avacta announce as encouraging on 1 June 2026 about AVA6000?

On 1 June 2026, Avacta announced positive preclinical salivary gland cancer results for faridoxorubicin (AVA6000), saying the results support confidence in its Gen One product and the pre|CISION tumour-targeting platform.

Updated 6 Oct 2026

Insight

How much gross proceeds did Avacta raise in its conditional placing and subscription on 29 September 2026?

On 29 September 2026, Avacta conditionally raised gross proceeds of £12.5 million via a placing of 17.41 million new ordinary shares and a subscription for 970,587 new shares, both priced at 68p.

Updated 6 Oct 2026

Insight

What revenue sources does Avacta Group publicly emphasise?

Publicly disclosed information emphasises research & development, collaborations and licensing as revenue sources for Avacta Group.

Updated 10 Jun 2026

Insight

Who acted as sole broker and bookrunner for Avacta Group’s 6 October 2026 placing?

Zeus Capital acted as sole broker and bookrunner for Avacta Group’s placing on 6 October 2026, with Beech Hill Securities as the US placing agent.

Updated 6 Oct 2026

Insight

How much cash did Avacta settle to reduce the principal balance on its convertible bond after a notice on 9 July 2026?

On 9 July 2026, Avacta settled a £3.67m accelerated amortisation payment in cash on its convertible bond, reducing the remaining principal balance to £16.8m.

Updated 6 Oct 2026

Identifiers

Ticker: AIM:AVCT
Market: AIM
ISIN: GB00BYYW9G87
LEI: 2138009U3EG31OPMGH36

Learn more on:

GLEIF Companies House

Timeline

Avacta

Avacta raises £12.5m in placing and subscription

Avacta unveils new AVA6103 data at pancreatic cancer conference

Avacta hits clinical proof of mechanism for AVA6103

Avacta settles £3.67m convertible bond payment in cash

FDA clears single pivotal trial path for Avacta's AVA6000 in salivary gland cancer

Avacta starts dosing patients in AVA6103 trial with cash runway extended to early 2027

Avacta Group raises £9m to repay debt

Avacta reports positive results in salivary gland cancer research

Avacta names Richard Hughes as non‑executive chairman

Avacta says pre|CISION releases payload faster and more selectively than approved ADCs

Avacta demonstrates AVA6103 outdelivers Enhertu and reveals dual‑payload in vivo data

Avacta to raise c.£10m via equity placing

More in Biotech

IP Group leads £4m funding round for AI materials spin-out

Genflow wins Japanese patent allowance for SIRT6 therapy

Scancell widens annual loss

Sareum signals intention to launch equity capital raise

OKYO Pharma enrolls first patients in Phase 3 neuropathic corneal pain trial

Poolbeg Pharma secures South Korean patent for POLB 001

Health & Bio Today: Fusion Antibodies refreshes platform after margin turnaround, Molecule Group

Fusion Antibodies relaunches website to sharpen customer focus

Cardiogeni shares suspended on delayed annual accounts

Imaging Biometrics builds US pipeline, rebrands core platform as IB Vista

Eden Research wins US label expansion for Mevalone

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer